Coenzyme Q10 and Its Therapeutic Potencies Against COVID-19 and Other Similar Infections: A Molecular Review

Mohammad Fakhrolmobashi1, Mahnaz-Sadat Hosseini2, Seyyed-Ghazal Shahrokh1, Zahra Mohammadi3, Mohammad-Javad Kahlani4, Seyed-Erfan Majidi1, Mehrdad Zeinalian1,4*1

1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
3Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.
4Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Sciences and Technologies, University of Isfahan, Isfahan, Iran.
5Pediatric Inherited Disease Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
6Iranians Cancer Control Charity Institute (MACSA), Isfahan, Iran.

Abstract

Purpose: New lethal coronavirus disease 2019 (COVID-19), currently, has been converted to a disastrous pandemic worldwide. As there has been found no definitive treatment for the infection in this review we focused on molecular aspects of coenzyme Q10 (CoQ10) and possible therapeutic potencies of CoQ10 against COVID-19 and similar infections.

Methods: This is a narrative review in which we used some authentic resources including PubMed, ISI, Scopus, Science Direct, Cochrane, and some preprint databases, the molecular aspects of CoQ10 effects, regarding to the COVID-19 pathogenesis, have been analyzed and discussed.

Results: CoQ10 is an essential cofactor in the electron transport chain of the phosphorylative oxidation system. It is a powerful lipophilic antioxidant, anti-apoptotic, immunomodulatory and anti-inflammatory supplement which has been tested for the management and prevention of a variety of diseases particularly diseases with inflammatory pathogenesis. CoQ10 is a strong anti-inflammatory agent which can reduce tumor necrosis factor-a (TNF-a), interleukin (IL)-6, C-reactive protein (CRP), and other inflammatory cytokines. The cardio-protective role of CoQ10 in improving viral myocarditis and drug induced cardiotoxicity has been determined in different studies. CoQ10 could also improve the interference in the RAS system caused by COVID-19 through exerting anti-Angiotensin II effects and decreasing oxidative stress. CoQ10 can reduce oxidative stress and modulate the immunologic reactions. These properties may help to reduce CNS inflammation and prevent BBB damage and neuronal apoptosis in COVID-19 patients.

Conclusion: CoQ10 supplementation may prevent the COVID-19-induced morbidities with a potential protective role against the deleterious consequences of the disease, further clinical evaluations are encouraged.

Introduction

After the report of the first case of coronavirus disease 2019 (COVID-19) on 31 December 2019 in China,1 the virus rapidly spread worldwide. The World Health Organization (WHO) officially declared COVID-19 as pandemic on 11 March 2020 and millions of people have so far died from the disease.2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the previously known viruses SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) are known to cause threatening epidemics with severe clinical features that mostly involve the respiratory system.3 Coronaviridae family consists of enveloped viruses containing large positive-sense single-stranded RNA genomes which is restricted within a protein capsid and their envelope is covered with glycoprotein spikes in the shape of crowns.4 The spikes contain receptor binding domains and facilitate the attachment and replication of the virus.5 Angiotensin converting enzyme 2 (ACE2) is known as the mutual receptor for SARS-CoV-2 and its similar ancestor SARS-CoV.6 ACE2 is considerably expressed in the lung epithelium, and its possible role in the pathogenesis of COVID-19 has been suggested in different studies.7 COVID-19 is currently considered the greatest health threat internationally and there is yet no definitive treatment for the disease. Therefore,
The role of CoQ₁₀ in a brief opinion had been mainly focused on the preventive and supportive approaches.⁴ As the virus continues to rapidly spread and infect millions of people, the urge to find a definite treatment intensifies and great research attempts are being conducted to solve this global concern.

Coenzyme Q₁₀ (CoQ₁₀) is a natural lipid soluble electron transporter found in the mitochondrial membrane. It is an essential cofactor in the electron transport chain of the phosphorylative oxidation system. This coenzyme molecule could undergo oxidation/reduction reactions,⁵ and act as a powerful lipophilic antioxidant, anti-apoptotic, immunomodulatory and anti-inflammatory supplement which has been tested for the management and prevention of a variety of diseases specially diseases with inflammatory pathogenesis.⁶ The role of CoQ₁₀ supplementation in heart failure and neurodegenerative diseases has been well established.⁷⁻⁸ Other clinical applications of CoQ₁₀ have been tested in several clinical trials on patients with inflammatory diseases such as rheumatoid arthritis, fatty liver and diabetes. CoQ₁₀ supplementation has presented ameliorative effects on serum inflammatory markers.⁹ Moreover, studies on critically ill and intensive care unit (ICU) patients have revealed a severe depletion of CoQ₁₀ levels. It may indicate that CoQ₁₀ supplementation solely or in combination with other micronutrients like carnitine and selenium could have a considerable positive effect on disease progression and treatment outcomes.¹⁰ Recent studies on CoQ₁₀ revealed the immunomodulatory effects of this coenzyme,¹¹⁻¹³ especially in the context of viral disorders. In fact, the systemic inflammation and hypercytokinemia caused by acute viral infections may become suppressed by immunomodulatory and anti-apoptotic properties of CoQ₁₀.¹⁴⁻¹⁶ Accordingly, some studies had reviewed the potential role of CoQ₁₀ and other mitochondrial nutrients as therapeutic options against the systemic inflammation and mitochondrial dysfunction in COVID-19. Polymeropoulos¹⁷ in a brief opinion had reviewed the anti-inflammatory effects of CoQ₁₀ in various clinical situation and encouraged further researches for assessing the correlation between the levels of CoQ₁₀ in human body and the outcomes of COVID-19. In another comprehensive review by Pagano et al,¹⁸ the evidences supporting the role of mitochondrial nutrients, such as α-lipoic acid, CoQ₁₀ and carnitine, against acute and chronic inflammatory conditions were summarized. In this review we aimed to discuss the molecular aspects of CoQ₁₀ supplementation against COVID-19. Herein, rather than the anti-inflammatory properties of CoQ₁₀, we described other various pathways that CoQ₁₀ supplementation could affect the disease pathogenesis including: antiviral, gene expression regulatory, immune modulatory, neuroprotective and cardiovascular protective properties of CoQ₁₀. In addition, the role of CoQ₁₀ supplementation in clinical setting particularly in critically ill patients was reviewed from a molecular point of view.

Materials and Methods

The current study is a narrative molecular review. Some authentic resources including PubMed, ISI, Scopus, ScienceDirect, Cochrane, and some preprint databases such as Arxiv were searched within 2000-2021. Some sensitive keywords were used to find the most relevant articles, such as molecular, CoQ₁₀, viral infection, COVID-19, SARS, and corona virus infection. Finally, the selected full-text articles were reviewed and using thematic analysis, the molecular aspects of CoQ₁₀ potencies against COVID-19 and other similar viral infections have been analyzed.

Results and Discussion

Molecular basis of SARS-CoV-2 infection and consequent clinical characteristics of the disease

binding of SARS-CoV-2 spike to transmembrane ACE2 is not only the first step in pathogenesis of COVID-19 but also is the most fundamental. In fact, the RNA entrance, replication and consequent cell damage is not the only pathologic concern of COVID-19.²⁰ As mentioned, the viral spike protein has a strong affinity to ACE2 and this is the key point of protein interaction and further deleterious clinical and pathological properties of COVID-19.²¹ ACE2 is a transmembrane enzyme producing angiotensin I (AngI) and a heptamer opposing the action of angiotensin II (AngII), which is correlated with the pathogenesis of several diseases like cardiovascular, renal and fibrotic diseases. Further studies about AngII revealed that besides its vasoconstrictor effect, the immunologic, inflammatory, fibrogenic and leukocyte migratory effects are also considerable aspects of this molecular axis. AngII signaling pathway is transmitted through two G-protein-coupled receptors called AT₁ and AT₂. The most concerns is about ACE/AngII/AT₁, route through which a variety of AngII adverse effects including: (1) oxidative stress production specially through NADPH oxidase enzyme upregulation, (2) inflammatory response by the activation of NF-κB translation factor and consequent tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production, (3) activating the leukocyte migratory pathway through increasing both the endothelial adhesion molecules like VCAMs and cell adhesion molecules on leukocytes, (4) contributing to endothelial dysfunction and (5) increasing the risk of arrhythmia and fibrosis through activating the proliferating pathways of fibroblasts and smooth muscle cells.²² Given the fact that these effects are all opposed by angiotensin II receptor blockers (ARBs) the pathophysiology of SARS-CoV-2 becomes easy to understand. The viral spike protein interaction suppresses the inhibitory effect of ACE2 on the AngII system and consequently over-activates AT₁, resulting in a propagated systemic inflammation and hypercytokininemia accompanied by immense oxidative stress in affected organs.²³ Current studies show that the secondary hemophagocytic lymphohistiocytosis as an hyperinflammatory status, which leads to...
hypercytokinemia, is a common reason for death after a multiorgan failure in patients infected by COVID-19.24 These events are characterized by a cytokine storm due to the fulminant increased cytokines includes IL-2, IL-7, granulocyte colony stimulating factor, interferon-γ, inducible protein 10 (IP-10), monocyte chemo-attractant protein 1 (MCP1), macrophage inflammatory protein 1-α (MIP-1α), and TNF-α.25 In another recent work, it was demonstrated that the CD4+ and CD8+ T cells counts in the patients with severe form of COVID-19 had been reduced in negative correlation with increased IL-6, IL-10 and TNF-α, suggesting the apoptotic effect of these factors on T cells.26 It was also demonstrated that the apoptotic pathway triggered by IL-10, IL-6 and TNF-α passes through mitochondrial stress which is pursued by the activated caspase-9 and caspase-3.27 The mentioned two phenomena, systemic inflammation and oxidative stress, are the main causes of almost all clinical events in COVID-19. Pneumonia in COVID-19 is not only due to the pulmonary epithelium infection but also the increased vascular permeability, leukocyte migration and vascular hyper-inflammation play an undeniable role in the pathophysiology of the disease.28 The pathophysiology of cardiovascular effects of COVID-19 is not completely understood, but most researchers consider cytokine storm and myocardial inflammation as the key contributors to the events.29 In very recent and novel studies, the neuro-infective properties of SARS-CoV-2 have been discussed.30–32 Steardo et al30 postulated that like SARS, MERS and other members of Coronaviridae, SARS-CoV-2 could infect the CNS and PNS causing neurologic impairment. The suggested mechanism of neuro-infection in COVID-19 is hematogenous and retrograde neuronal rout invasion to CNS. Furthermore, the systemic inflammatory state could cause the neuronal damage as made in many neuro-degenerative diseases. The first study about neurological involvement in COVID-19 patients ran in Wuhan, China, reported the neurological impairment and complications including: impaired consciousness, hyposmia, hypogeusia, dizziness, headache, and cerebrovascular accidents in severely ill patients, concluding that CNS and PNS involvement are signs of poor prognosis of the disease.31 Li et al33 discussed the association of respiratory failure with neuro-invasiveness of SARS-CoV-2 and demonstrated that viral invasion to the medullary cardiorespiratory centers through the root of mechanoreceptors and chemoreceptors in lower respiratory tract could cause respiratory failure in severely ill patients. (Figure 1).

Biochemical and pharmacological characteristics of coenzyme Q₁₀
In 1957 Crane et al34 reported the first time a quinone found in oxidized and reduced forms. Coenzyme Q₁₀ or CoQ₁₀ (2, 3dimethoxy-5methyl-6-decaprenyl benzoquinone) is a lipophilic vitamin-like compound which is also known as ubiquinone (oxidized) or ubiquinol (reduced). The chemical structure (Figure 2) consists of a benzoquinone ring connected to a long side chain containing 10 isoprene units.35 CoQ₁₀ is endogenously...
Further studies revealed other molecular functions of CoQ₁₀ metabolism has been postulated that the vitamin E is a lipid-soluble antioxidant which acts as a free radical scavenger and a membrane stabilizer, prevents phospholipid peroxidation, and regenerates vitamin E (α-tocopherol) and vitamin C (ascorbate). Kagan et al. postulated that the vitamin E regenerative property of this coenzyme is a more effective antioxidant than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role in the other form, it can be a very efficient antioxidant. Some enzymes such as NADH cytochrome b₅ reductase, NADPH coenzyme Q reductase and NADH/NADPH oxidoreductase are effective enzymes which can keep the body in a state of homeostasis and normal function. Therefore, these enzymes are necessary for the body to maintain its normal function, especially in energy-demanding tissues involved by the disease, such as heart and liver. CoQ₁₀ is expressed in all tissues. The body is not normally dependent on exogenous sources of CoQ₁₀, but its biosynthesis is decreased with age and also many critical conditions in which the serum and tissue levels of this coenzyme are reduced by oxidative stress. In such conditions, exogenous CoQ₁₀ is required to maintain the normal blood and tissue levels. CoQ₁₀ is absorbed as a lipid-soluble substance and its uptake increases with high fat food. The main absorption occurs in the small intestine without any specific receptors. In circulation, CoQ₁₀ is reduced to ubiquinol and then taken up rapidly by the liver where CoQ₁₀ is incorporated mostly into very low-density lipoprotein (VLDL)/low density lipoprotein (LDL) particles. CoQ₁₀ supplements have poor bioavailability in oral administration due to their insolubility in water and high molecular weight. CoQ₁₀ metabolism has not been well studied in humans, but studies in animal models suggest that CoQ₁₀ is metabolized in all tissues. The main route of the elimination of CoQ₁₀ is through bile and stool excretion. A small fraction of the metabolites is phosphorylated in the cells, transported to the kidneys through blood, and excreted in the urine.

**Figure 2.** The structure of Coenzyme Q₁₀.

CoQ₁₀: a powerful antioxidant and anti-inflammatory agent

An antioxidant is defined as a substance that inhibits or retards oxidation. CoQ₁₀ is a lipid-soluble antioxidant which acts as a free radical scavenger and a membrane stabilizer, prevents phospholipid peroxidation, and regenerates vitamin E (α-tocopherol) and vitamin C (ascorbate). Kagan et al. postulated that the vitamin E regenerative property of this coenzyme is a more effective antioxidant than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role in the other form, it can be a very efficient antioxidant. Some enzymes such as NADH cytochrome b₅ reductase, NADPH coenzyme Q reductase and NADH/NADPH oxidoreductase are effective enzymes which can keep the body in a state of homeostasis and normal function. Therefore, these enzymes are necessary for the body to maintain its normal function, especially in energy-demanding tissues involved by the disease, such as heart and liver. CoQ₁₀ is expressed in all tissues. The body is not normally dependent on exogenous sources of CoQ₁₀, but its biosynthesis is decreased with age and also many critical conditions in which the serum and tissue levels of this coenzyme are reduced by oxidative stress. In such conditions, exogenous CoQ₁₀ is required to maintain the normal blood and tissue levels. CoQ₁₀ is absorbed as a lipid-soluble substance and its uptake increases with high fat food. The main absorption occurs in the small intestine without any specific receptors. In circulation, CoQ₁₀ is reduced to ubiquinol and then taken up rapidly by the liver where CoQ₁₀ is incorporated mostly into very low-density lipoprotein (VLDL)/low density lipoprotein (LDL) particles. CoQ₁₀ supplements have poor bioavailability in oral administration due to their insolubility in water and high molecular weight. CoQ₁₀ metabolism has not been well studied in humans, but studies in animal models suggest that CoQ₁₀ is metabolized in all tissues. The main route of the elimination of CoQ₁₀ is through bile and stool excretion. A small fraction of the metabolites is phosphorylated in the cells, transported to the kidneys through blood, and excreted in the urine.

**Coenzyme Q₁₀ and medical molecular biology**

The primary physiological effect of CoQ₁₀ is described as a part of the cellular ATP synthesis system. CoQ₁₀ is a fundamental part of the oxidative phosphorylation of mitochondria. Five protein-lipid complexes situated in the inner mitochondrial membrane, which use molecular oxygen as the final electron acceptor, are engaged in oxidative phosphorylation. Complexes I–IV are responsible for the transportation of electrons to molecular oxygen. CoQ₁₀ is an electron carrier in this process. Finally, this process creates an electrochemical proton-motive force and the final complex (complex V) uses this force to form ATP. Further studies revealed other molecular properties of CoQ₁₀ as a powerful antioxidant, gene regulator, anti-inflammatory, and immune modulating agent which are discussed as following.

CoQ₁₀ is a powerful antioxidant and anti-inflammatory agent

An antioxidant is defined as a substance that inhibits or retards oxidation. CoQ₁₀ is a lipid-soluble antioxidant which acts as a free radical scavenger and a membrane stabilizer, prevents phospholipid peroxidation, and regenerates vitamin E (α-tocopherol) and vitamin C (ascorbate). Kagan et al. postulated that the vitamin E regenerative property of this coenzyme is a more effective antioxidant than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role as an anti-atherosclerotic property through diminishing the oxidation of LDL. CoQ₁₀ also upregulates some enzymatic antioxidants like superoxide dismutase (SOD) and glutathione peroxidase. The ubiquinone (oxidized form of CoQ₁₀) become reduced to ubiquinol through the enzymatic actions of NADH-cytochrome b₅ reductase and NAD(P)H:quinone oxidoreductase 1.

Researches on human body revealed that the production of CoQ₁₀ reduces through the ages. This contribute to the process of aging and aging related systemic inflammation. Inflammation is both the cause and the consequence of oxidative stress. CoQ₁₀ as an immunomodulatory and an antioxidant could rationally act as a strong anti-inflammatory agent. Moreover, in clinic, Various meta-analysis on RCTs strongly suggest that CoQ₁₀ significantly reduces TNF-α, IL-6 and C-reactive protein (CRP). In another study CoQ₁₀ treatment proves to have a role in reducing the mir146-a expression which is a regulation pathway to reduce oxidative stress than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role as an anti-atherosclerotic property through diminishing the oxidation of LDL. CoQ₁₀ also upregulates some enzymatic antioxidants like superoxide dismutase (SOD) and glutathione peroxidase. The ubiquinone (oxidized form of CoQ₁₀) become reduced to ubiquinol through the enzymatic actions of NADH-cytochrome b₅ reductase and NAD(P)H:quinone oxidoreductase 1.

Researches on human body revealed that the production of CoQ₁₀ reduces through the ages. This contribute to the process of aging and aging related systemic inflammation. Inflammation is both the cause and the consequence of oxidative stress. CoQ₁₀ as an immunomodulatory and an antioxidant could rationally act as a strong anti-inflammatory agent. Moreover, in clinic, Various meta-analysis on RCTs strongly suggest that CoQ₁₀ significantly reduces TNF-α, IL-6 and C-reactive protein (CRP). In another study CoQ₁₀ treatment proves to have a role in reducing the mir146-a expression which is a regulation pathway to reduce oxidative stress than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role as an anti-atherosclerotic property through diminishing the oxidation of LDL. CoQ₁₀ also upregulates some enzymatic antioxidants like superoxide dismutase (SOD) and glutathione peroxidase. The ubiquinone (oxidized form of CoQ₁₀) become reduced to ubiquinol through the enzymatic actions of NADH-cytochrome b₅ reductase and NAD(P)H:quinone oxidoreductase 1.

Researches on human body revealed that the production of CoQ₁₀ reduces through the ages. This contribute to the process of aging and aging related systemic inflammation. Inflammation is both the cause and the consequence of oxidative stress. CoQ₁₀ as an immunomodulatory and an antioxidant could rationally act as a strong anti-inflammatory agent. Moreover, in clinic, Various meta-analysis on RCTs strongly suggest that CoQ₁₀ significantly reduces TNF-α, IL-6 and C-reactive protein (CRP). In another study CoQ₁₀ treatment proves to have a role in reducing the mir146-a expression which is a regulation pathway to reduce oxidative stress than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role as an anti-atherosclerotic property through diminishing the oxidation of LDL. CoQ₁₀ also upregulates some enzymatic antioxidants like superoxide dismutase (SOD) and glutathione peroxidase. The ubiquinone (oxidized form of CoQ₁₀) become reduced to ubiquinol through the enzymatic actions of NADH-cytochrome b₅ reductase and NAD(P)H:quinone oxidoreductase 1.

Researches on human body revealed that the production of CoQ₁₀ reduces through the ages. This contribute to the process of aging and aging related systemic inflammation. Inflammation is both the cause and the consequence of oxidative stress. CoQ₁₀ as an immunomodulatory and an antioxidant could rationally act as a strong anti-inflammatory agent. Moreover, in clinic, Various meta-analysis on RCTs strongly suggest that CoQ₁₀ significantly reduces TNF-α, IL-6 and C-reactive protein (CRP). In another study CoQ₁₀ treatment proves to have a role in reducing the mir146-a expression which is a regulation pathway to reduce oxidative stress than the free radical scavenging characteristics of CoQ₁₀. The preventive effect of CoQ₁₀ against lipid peroxidation also plays a role as an anti-atherosclerotic property through diminishing the oxidation of LDL. CoQ₁₀ also upregulates some enzymatic antioxidants like superoxide dismutase (SOD) and glutathione peroxidase. The ubiquinone (oxidized form of CoQ₁₀) become reduced to ubiquinol through the enzymatic actions of NADH-cytochrome b₅ reductase and NAD(P)H:quinone oxidoreductase 1.
Coenzyme Q₁₀ has been identified as a modulator of several biological processes like cell signaling and has a vital role in the mitochondrial respiratory chain and antioxidant activity. Moreover, many in vitro and in vivo studies have demonstrated that CoQ₁₀, in addition to its well-known functions, affects the expression of several human genes involved in metabolism, cell signaling, nutrient transport, cell death and cell differentiation. Its diverse functions reflect its therapeutic potential as a dietary supplement for a number of diseases such as mitochondrial myopathies, migraine and cardiovascular diseases. On the other hand, the conversion of Q₁₀ into its reduced form is accompanied by the generation of reactive oxygen species (ROS) which may also have an additional impact on gene expression. A study conducted by Schmelzer et al presented that the reduced form of CoQ₁₀ (Q₁₀H₂) has a stronger effect on gene expression than the oxidized form CoQ₁₀, primarily due to differences in bioavailability. The endogenous insufficiency of CoQ₁₀ synthesis causes the up-regulation of oxidation reactions and the down-regulation of multiple genes which are crucial for growth such as RNA polymerase II. Exogenous CoQ₁₀ supplies partially restore the expression of these genes; however, the expression level of another subset of genes which are involved in some biological functions such as metabolism and cell signaling is not affected by exogenous CoQ₁₀ supplementation and depends solely on endogenous synthesis of CoQ₁₀. It has been further demonstrated that CoQ₁₀ supplementation may be effective in regulating the transcription factors contributing to inflammation and fibrosis. Pala et al postulated that CoQ₁₀ supplementation downregulate the expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and upregulate the anti-inflammatory pathways trough enhancing inhibitors of kappa B (IκB), nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and hemeoxygenase 1 (HO-1). In another study by Mohamed et al the downregulating effect of CoQ₁₀ supplementation on transforming growth factor (TGF)-β1 and matrix metalloproteinase (MMP)-9 was indicated. Consistent with the above mentioned animal studies, Armanfar et al reported the downregulating effect of CoQ₁₀ supplementation on IL-6, TNF-α in human subjects.

**Coenzyme Q₁₀: an immune-modulating agent**

The effect of CoQ10 supplementation on the immune system is a complexity of direct and indirect impacts on the energy metabolism, cell signaling and gene expression of the immune cells. The role of CoQ10 in normal ATP synthesis of mitochondria could considerably prevent the cellular stress and further apoptosis in ATP depleted activated immune cells. It is notable that the majority of immune cells involving in the regulation of the immune response use the mitochondrial pathways for ATP synthesis whereas pro-inflammatory immune cells mostly use the glycolysis pathway for ATP production. In view of cell signaling and differentiation of immune cells, studies had demonstrated that CoQ10 supplementation reduced the expression of p-STAT3 and further IL-17 while upregulates the expression of p-STAT5 and further FOXP3 which leads to differentiation of CD4 + T cells into regulatory T
cells rather than the pro-inflammatory T helper 17 cells. In one in-vitro study, the peripheral blood mononuclear cells were exposed to CoQ₁₀ for 24 h and the secretion of some cytokines was examined including IL-1β, IL-1RA, IL-6, IL-10, IL-2, INF-γ, TNF-α and IL-2. As a result, only TNF-α and IL-2 secretion was significantly decreased. Notably the outcome of this experiment presented that the treatment with an average concentration of 1.25µM CoQ₁₀ had the best effect, and the higher levels (up to 10µM) did not exert a significant difference. The different behavior of CoQ₁₀ in lower and higher dosages is suggestive of a biphasic role for CoQ₁₀. Moreover, in another study by Gollapudi and Gupta, CoQ₁₀ presented an apoptotic protective effect on CD4+ and CD8+ which had been induced with an oxidative stressor. The selected T cells after treatment with CoQ₁₀ (under 10µM concentration) for 24 h showed a strong resistance to an oxidative stress-induced mitochondrial apoptotic pathway. It represented that CoQ₁₀ could inhibit the activation of both caspase-9 and caspase-3 in apoptotic cascades. Moreover, it can reduce the production of ROS and prevent the oxidative stress-induced mitochondrial membrane depolarization in CD4+ and CD8+T cells. Another critical step in apoptotic process that is also suppressed by CoQ₁₀ is cytochrome C release from mitochondria according to some experimental studies. Furthermore, some studies demonstrated a lowered TNF-α secretion and a significant declined secretion of MIP-1α, MCP1 with CoQ₁₀ treatment on THP-1 cell line, the events which are very important in the COVID-19-induced hyper-inflammatory state. Since the monocytes are able to convert oxidized CoQ₁₀ into its reduced form, this reduction can be justified. NF-κB is a transcription factor for many genes involved in immune responses including which encode MIP-1α, MCP1, and TNF-α. It is believed that down-modulation of these factors is due to NF-κB inhibition. It has not been clearly confirmed that how CoQ₁₀ effects on NF-κB, but there are some evidences for NF-κB inhibition by antioxidant compounds (Figure 3).

**Coenzyme Q₁₀: an antiviral nutrient**

The viral infections, caused by RNA or DNA virus, trigger the production of reactive species (RS) and ROS including: NO, O₂⁻, OH⁻ and their by-products (such as H₂O₂), which interfere with normal functions of the infected cells such as gene expression and metabolism. As an instance, a higher RS level in the host cell promotes the activating of NF-κB which can lead to increased viral replication. There are also some evidences that antioxidant agents can mediate viral pathogenesis through the reinforcement of cell resistance against oxidative stress. Moreover, it has been determined that the antioxidant agents exert an important role in decreasing the replication of RNA viruses such as flaviviruses, alphaviruses, and Japanese encephalitis virus through the various pathways in different stages. Moreover, a recent molecular docking study of various quinone derivatives demonstrated that CoQ10 may indicate direct antiviral properties as CoQ₁₀ could effectively binds to the viral protein PDB 6Y84 protease of SARS-COV-2.

**Coenzyme Q₁₀ and anti-angiotensin II properties**

The renin–angiotensin system (RAS) has been shown to play a vital role in physiological and pathophysiological events in cardiovascular system. In this cascade, ACE converts AngI to AngII, and AngII as the prime component of RAS, disrupts endothelial function by increasing the oxidative stress. On the other hand, AngII and its receptor induce the activation of NADPH oxidase whereby the synthesis of ROS is increased. When the local levels of ROS are increased, a considerable cellular damage and oxidative stress will occur by interaction with cell membranes, DNA and other molecules.

Some experimental studies presented that CoQ₁₀ is involved in enhancing the expression of the antioxidant enzymes and eliminating the free radicals. Treatment with antioxidant agents may remove the misbalance of RAS caused by oxidative stress. Moreover, studies demonstrated the preventative effect of CoQ₁₀ against angiotensin induced up-regulation of NADPH oxidase enzyme.

**Clinical implications of coenzyme Q₁₀ in COVID-19**

CoQ₁₀ has been the subject of interest in a variety of diseases including cardiovascular, neurodegenerative, kidney and systemic inflammatory diseases. The antioxidant, anti-inflammatory, immunomodulatory and gene expression regulator properties of this molecule highlight its application as a considerable choice for nutrient therapy in the aforementioned diseases. Some of these conditions such as cardiovascular diseases, hyper-inflammatory state and critical stages of illnesses like septic shock share some features with COVID-19 in pathophysiology. The following statements describe this shared features and possible effects of CoQ₁₀ supplementation in COVID-19 patients.

**Coenzyme Q₁₀ and its potential cardioprotective effects**

CoQ₁₀ has a pivotal role in myocyte bioenergetics, exerts anti-inflammatory effects, and reduces oxidative stress. CoQ₁₀ supplementation could be beneficial for a wide spectrum of cardiovascular diseases including: heart failure, hypertension, myocardial infarction, viral myocarditis, arrhythmias, and drug-induced or idiopathic cardiomyopathies.

The action mechanism of this supplement, according to Greenberg and Ferishman, is to not only enhance the cellular aerobic metabolism but also exert cardiovascular effects including: the modification of endothelial dysfunction, preserving the function of the NA⁺/K⁺-ATPase, stabilizing the cellular membrane, reducing blood viscosity, modulating the immune system, and reducing blood viscosity, modulating the immune system.
Coenzyme Q₁₀ could be helpful for cardiac patients as a supplement that contribute to increasing mitochondrial phosphate/oxygen ratio, alleviating reperfusion injury after hypoxic conditions, modifying QRS duration abnormalities, and improve NYHA function class. Moreover, CoQ₁₀ improves extracellular SOD and flow-mediated-dilation, and protect against progressive left ventricular remodeling and fibrosis. Ultimately, CoQ₁₀ can reduce total cardiac events and could be protective against myocardial infarction, congestive heart failure, and dilated and drug-induced types of cardiomyopathies.

The protective role of CoQ₁₀ in improving viral myocarditis and drug induced cardiotoxicity introduces this supplement as an appropriate choice for the prevention of COVID-19 cardiovascular complications which is generally influenced by two factors: cytokine storm, and adverse effects of the medications. The hypercytokinemia caused by SARS-COV-2 infection could lead to fulminant myocarditis, a lethal condition mostly caused by hyper-inflammatory state and cytokine storms, particularly during a viral infection. Evidence has demonstrated that the blood levels of inflammatory cytokines in critically ill patients in the ICU are higher than the patients not admitted to the ICU; additionally, the level of IL-6 has shown to be higher in patients with cardiac injury. The anti-inflammatory, antioxidant, and immunomodulatory effects of CoQ₁₀ could suppress the hyper-inflammatory state, particularly through reducing IL-6, TNF-α and other inflammatory cytokines resulting in the prevention of cardiovascular events in COVID-19 patients and the alleviation of the cardiac complications caused by the cytokine storm in this disease.

Despite the fact that no definitive treatment for COVID-19 has yet been discovered, several curative and supportive medications have been suggested; the most fundamental of which include chloroquine, hydroxyl chloroquine, remdesivir, and potent antibiotics preventing bacterial super infections. Among the adverse effects of these drugs, particularly hydroxyl chloroquine, cardiovascular complications are of great importance. These drugs induce cardiotoxicity through increasing oxidative stress, triggering endothelial dysfunction and elevating tissue inflammation. CoQ₁₀ counteracts the cardio-toxic effects of these drugs by improving the mechanism of oxidative phosphorylation, reducing oxidative stress and decreasing the inflammation of the myocardium.

**Coenzyme Q₁₀ in critically ill and ICU patients**

The molecular and cellular mechanism of sepsis has not been entirely discovered and includes different aspects. One of the most crucial elements of sepsis is severe oxidative stress accompanied by the mitochondria dysfunction. The decreased levels of CoQ₁₀ during septic shock have also a significant importance. The elevated levels of IL-6 and IL-8 which have a negative relationship with CoQ₁₀ levels, and the decreased LDL that is the plasma carrier of the coenzyme lead to lower CoQ₁₀ levels during the occurrence of septic shock. The coenzyme inversely correlates with vascular endothelial biomarkers like VCAM and inflammatory cytokines like IL-10, and its decrease during septic shock, contributes to the organ failure related to the mitochondrial dysfunction.

Meanwhile, despite the providing stable and proper hemodynamic conditions along with the optimal oxygenation in the critically ill patients, death rates could not be reduced in these people. This clearly indicates that the substantial mitochondrial dysfunction in the critically ill patients prohibits using the oxygen to produce intracellular ATP even with proper oxygenation. CoQ₁₀ could not only counteract the oxidative stress in sepsis as a strong mitochondrial and membranous antioxidant, but could also suppress the production of ROS, increase cellular metabolism and enhance the patient’s response to oxygenation by alleviating the mitochondrial dysfunction through stabilizing the plasma membrane, sustaining the function of the NA⁺/K⁺ ATPase, and regulating the oxidative phosphorylation system. Nevertheless, according to evaluations and clinical trials, supplementation with CoQ₁₀ could not solely benefit critically ill patients and it is advised to prescribe CoQ₁₀ with Selenium as a...
crucial component of several metabolic enzymes and selenoproteins.\textsuperscript{11} (Figure 4).

\textbf{Coenzyme Q10 and its potential neuroprotective effects}

Most of neurodegenerative diseases like Alzheimer and Parkinson disease, despite their exclusive neurologic and molecular properties, share some common pathological aspects such as neuro-inflammation, excitotoxicity cascade induced neuronal apoptosis, and mitochondrial dysfunction in affected neurons.\textsuperscript{89} \textit{CoQ\textsubscript{10}} is a nutrients of interest in adjunctive therapy and the prevention of these types of age related diseases.\textsuperscript{90} \textit{CoQ\textsubscript{10}} with anti-inflammatory, antioxidant and immunomodulatory properties, could suppress the CNS inflammation in such diseases in addition to reducing oxidative stress and enhancing mitochondrial function.\textsuperscript{91} \textit{CoQ\textsubscript{10}} could also prevent neuronal apoptosis trough keeping mitochondrial permeability transition pores in closed conformation and blocking the apoptosis pathway induced by N-methyl D-aspartate (NMDA) glutamate receptors or non-NMDA glutamate receptors.\textsuperscript{92}

The suggested pathophysiology of neurologic involvement in COVID-19 patient is based on three events; a retrograde trans-synaptic infection of CNS, homogenous infection of CNS in the context of disrupted BBB due to hypercytokinemia and a systemic inflammation which causes both endothelium and astrocytes dysfunction in BBB, and the direct impact of systemic inflammation and oxidative stress on CNS and PNS causing neuronal damage and pathologic reactions in the supportive tissue of neurologic system, blood vessels, coagulation cascades and endothelium resulting in the cerebrovascular accidents.\textsuperscript{30,32}

\textit{CoQ\textsubscript{10}} as a lipophilic antioxidant which passes easily through BBB, has a direct effect on reducing oxidative stress and modulating the immunologic reactions, which could be beneficial through suppressing the systemic inflammation,\textsuperscript{96} preventing BBB damage,\textsuperscript{97} and neuronal apoptosis in COVID-19 patients.\textsuperscript{92} Accordingly, \textit{CoQ\textsubscript{10}} supplementation could prevent the developing CNS and PNS damage and further deleterious consequences like central respiratory failure, delirium and loss of conciseness, leading to a permanent brain injury and death\textsuperscript{11} (Figure 1).

\textbf{Conclusion}

COVID-19 as a pandemic lethal infection, currently, has no definite treatment. The interaction of virus-spike with ACE2 receptor leads to the down-regulation of ACE2 which could enhance the pathologic effects of AngII and disturb the AngII/Ang\textsubscript{(1-7)} ratio. It could result in a huge cytokine storm, and an extensive oxidative stress which are the molecular basis of the most complications induced by COVID-19. \textit{CoQ\textsubscript{10}} as an essential electron transporter in the phosphorylative oxidation system is a powerful lipophilic antioxidant, anti-apoptotic, immunomodulatory and anti-inflammatory supplement which has been tested for the management and prevention of a variety of diseases specially diseases with inflammatory pathogenesis. \textit{CoQ\textsubscript{10}} can decrease the important inflammatory cytokines and prevent the organ damages due to a huge oxidative stress. \textit{CoQ\textsubscript{10}} can be also a cardio-protective and neuroprotective agent through reducing the viral toxicity against cardiomyocytes and CNC neurons. Accordingly, \textit{CoQ\textsubscript{10}} supplementation could prevent the COVID-19-induced morbidities and has a potential protective role against the
deleterious consequences of the disease.

**Competing Interests**

All authors declare no conflict of interest.

**Ethical Approval**

Not applicable.

**References**

1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021.

2. Fehr AR, Perlman S. Coronavirus: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1-23. doi: 10.1007/978-1-4939-2438-7_1

3. Phan MVT, Ngo Ti T, Hong Anh P, Baker S, Kellam P, Cotten M. Identification and characterization of Coenzyme Q(10) isoforms from Vietnamese bats and rats based on conserved protein domains. Virus Evol 2018;4(2):vey035. doi: 10.1093/ve/vey035

4. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016;3(1):237-61. doi: 10.1146/annurev-virology-110615-042301

5. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;202(3):631-7. doi: 10.1002/path.1570

6. Ni W, Yang Y, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020;24(1):422. doi: 10.1186/s13054-020-03120-0

7. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20(6):591-8. doi: 10.1080/07315724.2001.10719063

8. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Biochemical functions of coenzyme Q10 in the treatment of heart failure: a systematic review of clinical trials. Pharmacol Res 2017;119:128-36. doi: 10.1016/j.phrs.2017.01.032

9. Jafari M, Mousavi SM, Asgharzadeh A, Yazdani N. Coenzyme Q10 in the treatment of heart failure: a systematic review of systematic reviews. Indian Heart J 2018;70(Suppl 1):S111-57. doi: 10.1016/j.ijhj.2018.01.031

10. Fan L, Feng Y, Chen GC, Qin LQ, Fu CL, Chen LH. Effects of coenzyme Q10 supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2017;119:128-36. doi: 10.1016/j.phrs.2017.01.032

11. Hargreaves JP, Dole S. Supplementation with selenium and coenzyme Q10 in critically ill patients. Br J Hosp Med (Lond) 2019;80(10):589-93. doi: 10.12968/bjhm.2019.80.10.589

12. Schmelzer C, Lorenz G, Lindner I, Rimbach G, Nieklochwitz P, Menke T, et al. Effects of coenzyme Q10 on TNF-α secretion in human and murine monocyte cell lines. Biofactors 2007;31(1):35-41. doi: 10.1002/bio.5520310104

13. Schmelzer C, Lorenz G, Rimbach G, Döring F. Influence of coenzyme Q10 on release of pro-inflammatory chemokines in the human monocyte cell line THP-1. Biofactors 2007;31(3-4):211-7. doi: 10.1002/bio.5520310308

14. Gollapudi S, Gupta S. Reversal of oxidative stress-induced apoptosis in T and B lymphocytes by coenzyme Q10 (CoQ10). Am J Clin Exp Immunol 2016;5(2):41-7.

15. Kishimoto C, Tomioka N, Nakayama Y, Miyamoto M. Antioxidant effects of coenzyme Q10 on experimental viral myocarditis in mice. J Cardiovasc Pharmacol 2003;42(3):588-92. doi: 10.109700005144-200311000-00002

16. Keleççi S, Elibiyoglu O, Sen V, Yolbaş I, Uluca U, Tı L, et al. The relationships between clinical outcome and the levels of total antioxidant capacity (TAC) and coenzyme Q (CoQ10) in children with pandemic influenza (H1N1) and seasonal flu. Eur Rev Med Pharmacol Sci 2012;16(8):1033-8.

17. Chase M, Cocchi MN, Liu X, Andersen LW, Holmberg MJ, Donnino MW. Coenzyme Q10 in acute influenza. Influenza Other Respir Viruses 2019;13(1):64-70. doi: 10.1111/irv.12608

18. Polymopoulos V. A potential role of coenzyme Q10 deficiency in severe SARS-CoV-2 infection. OBM Integrative and Complementary Medicine 2020;5(4):042. doi: 10.21926/obm-icm.202004042

19. Pagano G, Manfredi C, Pallardò FV, Ilyakovitch A, Tiano L, Trifuoggi M. Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, in the case of sepsis and COVID-19 pneumonia. Inflammm Res 2021;70(2):159-70. doi: 10.1007/s00011-020-01423-0

20. Hanfil TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations. Clin Infect Dis 2020;71(5):850-4. doi: 10.1093/cid/ciaa329

21. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 2020;92(7):726-30. doi: 10.1002/jmv.25785

22. Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169(3):477-92. doi: 10.1111/bph.12159

23. Wang L, Hu X, Zhang W, Tian F. Angiotensin (1-7) ameliorates angiotensin II-induced inflammation by inhibiting LOX-1 expression. Inflammm Res 2013;62(2):219-28. doi: 10.1007/s00011-012-0571-2

24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JN. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4. doi: 10.1016/s0140-6736(20)30628-0

25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. doi: 10.1016/s0140-6736(20)30183-5

26. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv [Preprint]. February 20, 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.02.18.2002436v1

27. Wescbe DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 2005;78(2):325-37. doi: 10.1189/jlb.0105017

28. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflamatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 2020;214:108393. doi: 10.1016/j.clim.2020.108393

29. Fakhrolmobasheri M, Khanahmad H, Kahlani MJ, Shiravi AA, Mohammedi M, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 2020;214:108393. doi: 10.1016/j.clim.2020.108393

30. Kafkholmobasher M, Khanahmad H, Kahlani MJ, Shiravi AA, Shahrokh SG, Zeinalian M. L-carnitine can extinguish the COVID-19 fire: a review on molecular aspects. Authorea. February 25, 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v1
Fakhrolmobasheri et al

32. Beckman Danielle, Bonillas Alyssa, Diniz Giovanni B, Ott Sean, Roh Jamin W, Elizalde Sonny R, et al. SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19. Cell Rep 2022;41(5):111573. doi: 10.1016/j.celrep.2022.111573.

33. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92(6):532-3. doi: 10.1002/jmv.25725.

34. Crane FL, Hafeti Y, Lester RL, Widmer C. Isolation of a quinine from beef heart mitochondria. Biochem Biophys Acta 1957;25(1):220-1. doi: 10.1016/0006-291X(57)90457-2.

35. Bank G, Kagan D, Madhavi D. Coenzyme Q10: clinical update and bioavailability. J Evid Based Complementary Altern Med 2011;16(2):129-37. doi: 10.1177/1524804311413082.

36. Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors 2003;18(1-4):129-36. doi: 10.1002/bnf.200301025.

37. Yang YK, Wang LP, Chen L, Yao XP, Yang KQ, Gao LG, et al. Coenzyme Q10 treatment of cardiovascular disorders of ageing including heart failure, hypertension and endothelial dysfunction. Clin Chim Acta 2015;450:83-9. doi: 10.1016/j.cca.2015.08.002.

38. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol 2014;49:105-11. doi: 10.1016/j.biocel.2014.01.020.

39. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006;40(5):445-53. doi: 10.1080/10715760600617843.

40. Folkers K, Wolanki A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 1985;11(8):539-45.

41. Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, Ferrández Vega A, de la Mata M, Delgado Pavón A, et al. Coenzyme q10 therapy. Mol Syndromol 2014;5(3-4):187-97. doi: 10.1016/j.mynos.2014.08.002.

42. Mohammed-Javad NK, Al-Sabbagh M, Al-Jeezaeri KA. Role of L-carnitine and coenzyme Q10 as adjuvant therapy in patients with type 2 diabetes mellitus. Am J Pharm Sci 2014;2(5):82-6. doi: 10.12969/ajps.2-5-2.

43. Negida A, Menshawy E, El Ashal G, Elfouly Y, Hany Y, Hegazy Mohamed HA, Said RS. Coenzyme Q10 attenuates inflammation and fibrosis implicated in radiation enteropathy through suppression of NF-κB/βC-MMP-9 pathways. Int Immunopharmacol 2021;92:107347. doi: 10.1016/j.intimp.2020.107347.

44. Armamar M, Jafari A, Dehghan GR, Abdizadeh L. Effect of coenzyme Q10 supplementation on exercise-induced response of inflammatory indicators and blood lactate in male runners. Med J Isl Rep Iran 2015;29:202.

45. Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10 and immune function: an overview. Antioxidants (Basel) 2021;10(5):759. doi: 10.3390/antiox10050759.

46. Faas MM, de Vos P. Mitochondrial function in immune cells in health and disease. Biochim Biophys Acta Mol Basis Dis 2020;1866(10):165845. doi: 10.1016/j.bbadis.2020.165845.

47. Lee SY, Lee SH, Yang EJ, Kim JK, Kim EK, Jung K, et al. Coenzyme Q10 inhibits Th17 and STAT3 signaling pathways to ameliorate colitis in mice. J Med Food 2017;20(9):821-9. doi: 10.1089/jmf.2016.3859.

48. Sumi K, Okura T, Fujikyo Y, Kato M, Immamura T, Taniguchi SI, et al. Coenzyme Q10 suppresses apoptosis of mouse pancreatic β-cell line MIN6. Diabetol Metab Syndr 2018;10:47. doi: 10.1186/s13098-018-0351-4.

49. Zhang Y, Wang Z, Chen H, Chen Z, Tian Y. Antioxidants: potential antiviral agents for Japanese encephalitis virus infection. Int J Infect Dis 2014;24:30-6. doi: 10.1016/j.ijid.2014.02.011.

50. Camini FC, da Silva Caetano CC, Almeida LT, de Brito Magalhães CL. Implications of oxidative stress on viral pathogenesis. Arch Virol 2017;162(4):907-17. doi: 10.1007/s00705-016-3187-y.

51. Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med 1996;21(5):641-9. doi: 10.1016/0891-5849(96)00131-1.

52. Roncati L, Galgo G, Manteni A, Palmieri B. Renin-angiotensin system: the unexpected flaw inside the human immune system...
revealed by SARS-CoV-2. Med Hypotheses 2020;140:109686. doi: 10.1016/j.mehy.2020.109686

67. Caruso F, Rossi M, Pedersen JZ, Incerpi S. Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone. J Infect Public Health 2020;13(12):1868-77. doi: 10.1016/j.jiph.2020.09.015

68. El Assar M, Angulo J, Rodríguez-Mañas L. Oxidative stress and vascular inflammation in aging. Free Radic Biol Med 2013;65:380-401. doi: 10.1016/j.freeradbiomed.2013.07.003

69. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30(7):596-608. doi: 10.1002/j.1552-4604.1990.tb01862.x

70. Tsuneki H, Tokai E, Suzuki T, Seki T, Okubo K, Wada T, et al. Protective effects of coenzyme Q10 against angiotensin II-induced oxidative stress in human umbilical vein endothelial cells. Eur J Pharmacol 2013;701(1-3):218-27. doi: 10.1016/j.ejphar.2012.12.027

71. Zozina VI, Covantev S, Goroshko OA, Kraşnykh LM, Kukes VG. Coenzyme Q10 in cardiovascular and metabolic diseases: current state of the problem. Curr Cardiol Rev 2018;14(3):164-74. doi: 10.2174/15734031466616115428

72. Littaruu GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition 2010;26(3):250-4. doi: 10.1016/j.nut.2009.08.008

73. Singh RB, Fedacko J, Mojto V, Pella D. Coenzyme Q10 modulates remodeling possibly by decreasing angiotensin II induced oxidative stress in patients with acute coronary syndrome. Antioxidants (Basel) 2018;7(8):99. doi: 10.3390/antiox7080099

74. Sarter B. Coenzyme Q10 and cardiovascular disease: a review. J Cardiovas Nurs 2002;16(4):9-20. doi: 10.1097/00005082-200207000-00003

75. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 2020;45(3):230-2. doi: 10.1007/s00059-020-04909-x

76. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360(15):1526-38. doi: 10.1056/NEJMra0800028

77. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017;2:17023. doi: 10.1038/sigtrans.2017.23

78. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol 2020;92(5):479-90. doi: 10.1002/jmv.25707

79. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020;383(19):1813-26. doi: 10.1056/NEJMoa2007764

80. Mladěnka P, Applová L, Patočka J, CostaVM, Remíja F, Pourková J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev 2018;38(4):1332-403. doi: 10.1002/med.21476

81. Tönnesmann E, Kandolf R, Lewalter T. Chlooroquine cardiomyopathy-a review of the literature. Immunopharmacol Immunotoxicol 2013;35(3):434-42. doi: 10.3109/08923973.2013.780078

82. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;15 Suppl:S265-72. doi: 10.1016/0098-2997(94)90037-x

83. Dinh QN, Drummond GR, Sobey CG, Chriisobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int 2014;2014:406960. doi: 10.1155/2014/406960

84. Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev 2016;3(3):CD007435. doi: 10.1002/14651858. CD007435.pub3

85. Mantzaris K, Tsalik V, Zakynthinos E. Role of oxidative stress and mitochondrial dysfunction in sepsis and potential therapies. Oxid Med Cell Longev 2017;2017:3985209. doi: 10.1155/2017/3985209

86. Dominno MW, Cocchi MN, Saliccioli JD, Kim D, Naini AB, Buettner C, et al. Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock. Crit Care 2011;15(4):R189. doi: 10.1186/cc10343

87. Cocchi MN, Giberson B, Berg K, Saliccioli JD, Naini A, Buettner C, et al. Coenzyme Q10 levels are low and associated with increased mortality in post-cardiac arrest patients. Resuscitation 2012;83(8):991-5. doi: 10.1016/j.resuscitation.2012.03.023

88. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995;333(16):1025-32. doi: 10.1056/NEJM199510193331601

89. Relja M. Pathophysiology and classification of neurodegenerative diseases. EJFCC 2004;15(3):97-9.

90. Galpern WR, Cidakowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Med Res Rev 2007;7 Suppl:S146-53. doi: 10.1002/med.21476

91. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 1999;9(2-4):261-6. doi: 10.1002/biof.5520090222

92. Martucci A, Nucci C. Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma. Cochrane Database Syst Rev 2017;8(9):91. doi: 10.1002/14651858.CD007435.pub3